Intratumoral heterogeneity in glioblastoma: Don't forget the peritumoral brain zone

Neuro-Oncology

Volumn 17, Issue 10, 2015, Pages 1322-1332

  LemCrossed D Sign©e, Jean Michel ^a,b   Clavreul, Anne ^a,b   Menei, Philippe ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

glioblastoma; histology; omics; peritumoral brain zone; radiology; targeted therapies

Indexed keywords

BEVACIZUMAB; NANOCAPSULE; TUMOR MARKER;

ARTICLE; ASTROCYTE; BRAIN REGION; CANCER INFILTRATION; CANCER RECURRENCE; CANCER SURGERY; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERITUMORAL BRAIN ZONE; PROGNOSIS; STROMA CELL; TUMOR CELL; BRAIN NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NANOCAPSULES; NEOPLASM RECURRENCE, LOCAL;

EID: 84943371331     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov119     Document Type: Article

References (122)

1. Loiseau H, Huchet A, Rué M, et al. [Epidemiology of primary brain tumor] [in French]. Rev Neurol (Paris). 2009;165(8-9):650-670.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Aum DJ, Kim DH, Beaumont TL, et al. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus. 2014;37(6):E11.
4. Friedmann-Morvinski D. Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog. 2014;19(5):327-336.
5. Burger PC, Kleihues P. Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer. 1989;63(10):2014-2023.
6. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396-1401.
7. Scherer HJ. The forms of growth in gliomas and their practical significance. Brain. 1940;63(1):1-35.
8. Meyer M, Reimand J, Lan X, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA. 2015;112(3):851-856.
9. Soeda A, Hara A, Kunisada T, et al. The evidence of glioblastoma heterogeneity. Sci Rep. 2015;5:7979.
10. Eder K, Kalman B. Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol Oncol Res. 2014;20(4):777-787.
11. Sottoriva A, Spiteri I, Piccirillo SGM, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013;110(10):4009-4014.
12. Aubry M, de Tayrac M, Saikali S, et al. "From the core to beyond the margin": a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget. 2015;6(14):12094-12109.
13. Stieber D, Golebiewska A, Evers L, et al. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol. 2014;127(2):203-219.
14. Petrecca K, Guiot M-C, Panet-Raymond V, et al. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol. 2013;111(1):19-23.
15. Clavreul A, Etcheverry A, Chassevent A, et al. Isolation of a new cell population in the glioblastoma microenvironment. J Neurooncol. 2012;106(3):493-504.
16. Clavreul A, Guette C, Faguer R, et al. Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties. J Pathol. 2014;233(1):74-88.
17. Com E, Clavreul A, Lagarrigue M, et al. Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma. J Proteomics. 2012;75(13):3898-3913.
18. Lemeé J-M, Com E, Clavreul A, et al. Proteomic analysis of glioblastomas: what is the best brain control sample J Proteomics. 2013;85:165-173.
19. De Tayrac M, Etcheverry A, Aubry M, et al. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer. 2009;48(1): 55-68.
20. De Tayrac M, Aubry M, Säkali S, et al. A 4-gene signature associated with clinical outcome in high-grade gliomas. Clin Cancer Res. 2011;17(2):317-327.
21. De Tayrac M, Saikali S, Aubry M, et al. Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas. PloS One. 2013;8(9):e73332.
22. Etcheverry A, Aubry M, de Tayrac M, et al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics. 2010;11:701.
23. Lemeé J-M, Clavreul A, Aubry M, et al. Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis. J Neurooncol. 2015;122(1):53-61.
24. Clavreul A, Etcheverry A, Té taud C, et al. Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins. J Neurooncol. 2015;122(1):1-10.
25. Glas M, Rath BH, Simon M, et al. Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol. 2010;68(2): 264-269.
26. Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg. 1997;86(3):525-531.
27. Nakai K, Nawashiro H, Shima K, et al. An analysis of T2 mapping on brain tumors. Acta Neurochir Suppl. 2013;118:195-199.
28. Pauleit D, Langen K-J, Floeth F, et al. Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas J Magn Reson Imaging. 2004;20(5):758-764.
29. Min Z, Niu C, Rana N, et al. Differentiation of pure vasogenic edema and tumor-infiltrated edema in patients with peritumoral edema by analyzing the relationship of axial and radial diffusivities on 3.0 T MRI. Clin Neurol Neurosurg. 2013; 115(8):1366-1370.
30. Wijnen JP, Idema AJS, Stawicki M, et al. Quantitative short echo time 1H MRSI of the peripheral edematous region of human brain tumors in the differentiation between glioblastoma, metastasis, and meningioma. J Magn Reson Imaging. 2012;36(5): 1072-1082.
31. Zhang N, Zhang L, Qiu B, et al. Correlation of volume transfer coefficient Ktrans with histopathologic grade s of gliomas. J Magn Reson Imaging. 2012;36(2):355-363.
32. Jensen RL, Mumert ML, Gillespie DL, et al. Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol. 2014;16(2):280-291.
33. Jalali S, Chung C, Foltz W, et al. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol. 2014;16(6):868-879.
34. Sundgren PC, Fan X,Weybright P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging. 2006;24(9):1131-1142.
35. Deng Z, Yan Y, Zhong D, et al. Quantitative analysis of glioma cell invasion by diffusion tensor imaging. J Clin Neurosci. 2010; 17(12):1530-1536.
36. Lu S, Ahn D, Johnson G, et al. Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology. 2004; 232(1):221-228.
37. Kinoshita M, Goto T, Okita Y, et al. Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema. J Neurooncol. 2010;96(3):409-415.
38. Cuddapah VA, Robel S, Watkins S, et al. A neurocentric perspective on glioma invasion. Nat Rev Neurosci. 2014;15(7): 455-465.
39. Piccirillo SGM, Dietz S, Madhu B, et al. Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer. 2012;107(3):462-468.
40. Ruiz-Ontanoñ P, Orgaz JL, Aldaz B, et al. Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells. 2013;31(6):1075-1085.
41. Toussaint LG, Nilson AE, Goble JM, et al. Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Mol Cancer. 2012;11:32.
42. Rampazzo E, Della Puppa A, Frasson C, et al. Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery. J Neurooncol. 2014;116(3):505-513.
43. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35.
44. Lin Q, Balasubramanian K, Fan D, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010;12(9):748-754.
45. Fitzgerald DP, Palmieri D, Hua E, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis. 2008; 25(7):799-810.
46. Seike T, Fujita K, Yamakawa Y, et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin Exp Metastasis. 2011;28(1):13-25.
47. Rath BH, Fair JM, Jamal M, et al. Astrocytes enhance the invasion potential of glioblastoma stem-like cells. PloS One. 2013;8(1): e54752.
48. Kim J-K, Jin X, Sohn Y-W, et al. Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. Cancer Lett. 2014;353(2):194-200.
49. Nagashima G, Suzuki R, Asai J, et al. Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg. 2002;104(2):125-131.
50. Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia. 2012;60(3):502-514.
51. Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol. 2014;128(3): 347-362.
52. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999;5(5):1107-1113.
53. Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15-24.
54. Engler JR, Robinson AE, Smirnov I, et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PloS One. 2012;7(8):e43339.
55. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264-1272.
56. Bowman RL, Joyce JA. Therapeutic targeting of tumorassociated macrophages and microglia in glioblastoma. Immunotherapy. 2014;6(6):663-666.
57. Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg. 2009;110(3):572-582.
58. Romá n-Pé rez E, Casbas-Hernández P, Pirone JR, et al. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res. 2012; 14(2):R51.
59. Mangiola A, Lama G, Giannitelli C, et al. Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res. 2007;13(23):6970-6977.
60. Sica G, Lama G, Anile C, et al. Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int J Oncol. 2011;38(1):41-49.
61. Lama G, Mangiola A, Anile C, et al. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int J Oncol. 2007;30(6):1333-1342.
62. Dehnhardt M, Zoriy MV, Khan Z, et al. Element distribution is altered in a zone surrounding human glioblastoma multiforme. J Trace Elem Med Biol. 2008;22(1):17-23.
63. Haybaeck J, Obrist P, Schindler CU, et al. STAT-1 expression in human glioblastoma and peritumoral tissue. Anticancer Res. 2007;27(6B):3829-3835.
64. Synowitz M, Glass R, Fä rber K, et al. A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res. 2006;66(17):8550-8557.
65. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
66. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425-437.
67. Mangiola A, Saulnier N, De Bonis P, et al. Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PloS One. 2013;8(3):e57145.
68. Gill BJ, Pisapia DJ, Malone HR, et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci USA. 2014;111(34):12550-12555.
69. Piwecka M, Rolle K, Belter A, et al. Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol. 2015;pii:S1574-7891(15)00056-3.
70. Godlewski J, Nowicki MO, Bronisz A, et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010;37(5):620-632.
71. Godlewski J, Newton HB, Chiocca EA, et al. MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ. 2010; 17(2):221-228.
72. Bastien JIL, McNeill KA, Fine HA. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer. 2015;121(4):502-516.
73. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
74. Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(21): 2048-2049.
75. Thaci B, Brown CE, Binello E, et al. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol. 2014;16(10):1304-1312.
76. Addeo R, Zappavigna S, Parlato C, et al. Erlotinib: early clinical development in brain cancer. Expert Opin Investig Drugs. 2014; 23(7):1027-1037.
77. Cuddapah VA, Turner KL, Seifert S, et al. Bradykinin-induced chemotaxis of human gliomas requires the activation of KCa3.1 and ClC-3. J Neurosci. 2013;33(4):1427-1440.
78. Ishiuchi S, Tsuzuki K, Yoshida Y, et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med. 2002; 8(9):971-978.
79. Nowicki MO, Dmitrieva N, Stein AM, et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol. 2008;10(5):690-699.
80. Williams SP, Nowicki MO, Liu F, et al. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res. 2011; 71(16):5374-5380.
81. Agudelo-Garcia PA, De Jesus JK, Williams SP, et al. Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. Neoplasia. 2011;13(9):831-840.
82. Wang M, Li C, Nie H, et al. Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett. 2012;586(16):2382-2388.
83. Svendsen A, Verhoeff JJC, Immervoll H, et al. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol. 2011;122(4):495-510.
84. Chekenya M, Enger P, Thorsen F, et al. The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol. 2002;28(5):367-380.
85. Hatanpaa KJ, Hu T, Vemireddy V, et al. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. J Neurooncol. 2014;117(1):183-189.
86. Akiyama M, Matsuda Y, Ishiwata T, et al. Inhibition of the stem cell marker nestin reduces tumor growth and invasion of malignant melanoma. J Invest Dermatol. 2013;133(5): 1384-1387.
87. Stockwell J, Abdi N, Lu X, et al. Novel central nervous system drug delivery systems. Chem Biol Drug Des. 2014;83(5):507-520.
88. Tajes M, Ramos-Fernández E, Weng-Jiang X, et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol. 2014;31(5):152-167.
89. Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. BioMed Res Int. 2015; 2015:320941.
90. Huynh NT, Passirani C, Saulnier P, et al. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379(2):201-209.
91. Burgess A, Hynynen K. Drug delivery across the blood-brain barrier using focused ultrasound. Expert Opin Drug Deliv. 2014; 11(5):711-721.
92. Lonser RR, Sarntinoranont M, Morrison PF, et al. Convection-enhanced delivery to the central nervous system. J Neurosurg. 2015;122(3):697-706.
93. Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol. 2015;17(Suppl 2): ii3-ii8.
94. Roger M, Clavreul A, Venier-Julienne M-C, et al. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials. 2011;32(8): 2106-2116.
95. Chekhonin VP, Baklaushev VP, Yusubalieva GM, et al. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43. Nanomedicine. 2012;8(1): 63-70.
96. Allard E, Huynh NT, Vessiè res A, et al. Dose effect activity of ferrocifen-loaded lipid nanocapsules on a 9L-glioma model. Int J Pharm. 2009;379(2):317-323.
97. Laine A-L, Huynh NT, Clavreul A, et al. Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. Eur J Pharm Biopharm. 2012;81(3):690-693.
98. Vanpouille-Box C, Lacoeuille F, Belloche C, et al. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. Biomaterials. 2011;32(28):6781-6790.
99. David S, Montier T, Carmoy N, et al. Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model. J Gene Med. 2012;14(12):769-775.
100. Resnier P, David S, Lautram N, et al. EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. Int J Pharm. 2013;454(2):748-755.
101. Griveau A, Bejaud J, Anthiya S, et al. Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death. Int J Pharm. 2013;454(2):765-774.
102. Vinchon-Petit S, Jarnet D, Michalak S, et al. Local implantation of doxorubicin drug eluting beads in rat glioma. Int J Pharm. 2010; 402(1-2):184-189.
103. Roger M, Clavreul A, Venier-Julienne M-C, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials. 2010;31(32):8393-8401.
104. Roger M, Clavreul A, Sindji L, et al. In vitro and in vivo interactions between glioma and marrow-isolated adult multilineage inducible (MIAMI) cells. Brain Res. 2012;1473:193-203.
105. Roger M, Clavreul A, Huynh NT, et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm. 2012;423(1):63-68.
106. Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012;117(5):851-859.
107. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16(1):113-122.
108. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients withmalignant brain astrocytoma. J Neurosurg. 2009;110(1):156-162.
109. Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12(11):997-1003.
110. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
111. Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. Cochrane Database Syst Rev. 2014; 1:CD009685.
112. Valdés PA, Kim A, Brantsch M, et al. d-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol. 2011;13(8): 846-856.
113. Assayag O, Grieve K, Devaux B, et al. Imaging of non-tumorous and tumorous human brain tissues with full-field optical coherence tomography. NeuroImage Clin. 2013;2:549-557.
114. Chen Y, Aguirre AD, Ruvinskaya L, et al. Optical coherence tomography (OCT) reveals depth-resolved dynamics during functional brain activation. J Neurosci Methods. 2009;178(1): 162-173.
115. Debarbieux F. [Towards a dynamic anatomopathology of glioblastoma in mice thanks to in vivo biphotonic microscopy]. Ann Pathol. 2010;30(5 Suppl 1):53-55.
116. Lemeé J, Clavreul A, Rakotoarimalala S, et al. P16.20 analysis of glioblastoma's peritumoral brain zone using biphotonic microscopy. Neuro Oncol. 2014;16(suppl 2):ii82-ii83.
117. Martirosyan NL, Cavalcanti DD, Eschbacher JM, et al. Use of in vivo near-infrared laser confocal endomicroscopy with indocyanine green to detect the boundary of infiltrative tumor. J Neurosurg. 2011;115(6):1131-1138.
118. Bö hringer HJ, Lankenau E, Stellmacher F, et al. Imaging of human brain tumor tissue by near-infrared laser coherence tomography. Acta Neurochir (Wien). 2009;151(5):507-517.
119. Kalkanis SN, Kast RE, Rosenblum ML, et al. Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections. J Neurooncol. 2014; 116(3):477-485.
120. Rutka JT, Kim B, Etame A, et al. Nanosurgical resection of malignant brain tumors: beyond the cutting edge. ACS Nano. 2014;8(10):9716-9722.
121. Tanahashi K, Natsume A, Ohka F, et al. Assessment of tumor cells in a mouse model of diffuse infiltrative glioma by Raman spectroscopy. BioMed Res Int. 2014;2014:860241.
122. Karabeber H, Huang R, Iacono P, et al. Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. ACS Nano. 2014;8(10):9755-9766.